Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Original) A method for treating, preventing the progression, ameliorating, controlling or reducing the risk of a movement disorder in a patient in need thereof that comprises administering to the patient a therapeutically effective amount of an mGluR4 receptor positive allosteric modulator or a pharmaceutically acceptable salt thereof.

Claim 2 (Cancelled)

Claim 3 (Original) The method of Claim 1 wherein the movement disorder is selected from the group consisting of Parkinson's disease, dyskinesia, tardive dyskinesia, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonian-ALS dementia complex, basal ganglia calcification, akinesia, akinetic-rigid syndrome, bradykinesia, dystonia, medication-induced parkinsonia, Gilles de la Tourette syndrome, Huntington's disease, tremor, chorea, myoclonus, tick disorder, and dystonia.

Claims 4-5 (Cancelled)

Claim 6 (Previously presented) The method of Claim 1 wherein the mGluR4 receptor positive allosteric modulator or a pharmaceutically acceptable salt thereof, is administered in combination with an agent selected from the group consisting of: levodopa, levodopa with a selective extracerebral decarboxylase inhibitor, carbidopa, entacapone, an anticholinergic, a COMT inhibitor, an A2a adenosine receptor antagonist, a cholinergic agonist, a dopamine agonist, a butyrophenone neuroleptic agent, a diphenylbutylpiperidine neuroleptic agent, a heterocyclic dibenzazepine neuroleptic agent, a indolone neuroleptic agent, a phenothiazine neuroleptic agent, a thioxanthene neuroleptic agent, an NMDA receptor antagonist, a metabotropic glutamate receptor potentiator and a metabotropic glutamate receptor agonist.

Claim 7 (Previsously presented) The method of Claim 1 wherein the mGluR4 receptor positive allosteric modulator or a pharmaceutically acceptable salt thereof, is administered in combination with a compound selected from the group consisting of: acetophenazine, alentemol, benzhexol, bromocriptine, biperiden, chlorpromazine, chlorprothixene, clozapine, diazepam, fenoldopam, fluphenazine, haloperidol, levodopa, levodopa with benserazide, levodopa with carbidopa, lisuride, loxapine, mesoridazine,

molindolone, naxagolide, olanzapine, pergolide, perphenazine, pimozide, pramipexole, risperidone, sulpiride, tetrabenazine, trihexyphenidyl, thioridazine, thiothixene and trifluoperazine.

Claims 8-9 (Cancelled)

Claim 10 (Previously presented) The method of Claim 1 wherein the mGluR4 receptor positive allosteric modulator is N-phenyl-7-(hydroxylimino)cyclo-propa[b]chromen-1a-carboxamide.

Claim 11 (Original) A pharmaceutical composition comprising an mGluR4 receptor positive allosteric modulator or a pharmaceutically acceptable salt thereof and an antiparkinsonian agent, and a pharmaceutically acceptable carrier or excipient.

Claim 12 (Original) A pharmaceutical composition comprising an mGluR4 receptor positive allosteric modulator or a pharmaceutically acceptable salt thereof and a neuroleptic agent, and a pharmaceutically acceptable carrier or excipient.

Claim 13 (Cancelled)

Claim 14 (Previously presented) The method of Claim 1 wherein the movement disorder is Parkinson's Disaese.

Claim 15 (Previously presented) The method of Claim 1 wherein the movement disorder is an akinetic rigid disorder.

Claim 16 (Previously presented) The method of Claim 1 wherein the movement disorder is dyskinesia.

Claim 17 (Previously presented) The method of Claim 15, wherein the patient in need thereof is non-responsive to antiparkinsonian agents or is a patient for whom antiparkinsonian agents are contraindicated.

Claim 18 (Previously presented) The method of Claim 16, wherein the patient in need thereof is non-responsive to neuroleptic agents or is a patient for whom neuroleptic agents are contraindicated.